DIAGNOSIS, TREATMENT AND OUTCOME OF LUNG CANCER PATIENTS

Study Overview
=================
Brief Summary
-----------------
Observational, prospective clinical research, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Turkey

Detailed Description
-----------------
In Turkey, non-small cell lung cancer (NSCLC) is the most common cause of cancer-related death in men and one of the most common causes of cancer-related deaths in women. Because of the heterogeneity of NSCLC or SCLC, it is crucial to characterize the biology of the tumor as exact as possible, to predict the course of disease as accurate as possible, and to determine the optimal therapeutic algorithm as early as possible after initial diagnostic work-up. These efforts are an obligatory part of the initial diagnostics, since thorough knowledge of the biology of the disease and the resulting therapeutic options ensure optimal care of Volunteers with NSCLC or SCLC. The aim of REGISTURK is to set up a national clinical research platform to document molecular testing, treatment and course of disease of patients with NSCLC or SCLC.

Official Title
-----------------
REGISTRY PLATFORM INTO DIAGNOSIS, TREATMENT AND OUTCOME OF LUNG CANCER PATIENTS

Conditions
-----------------
Non Small Cell Lung Cancer, Small-cell Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient histopathologically diagnosed with non-small cell lung cancer or small cell lung cancer Written informed consent no later than six weeks after start of first-line treatment Age ≥ 18 years Exclusion Criteria: Volunteers participating in a research program for non-small cell or small cell lung cancer that includes interventions outside of routine clinical trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of molecular/mutational analysis | To collect data on the frequency of molecular/mutational biomarker testing | throughout of treatment, 36 months | 
| Type of molecular/mutational analysis | To collect data on the type of molecular/mutational biomarker testing | throughout of treatment, 36 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Type of treatment | To describe systemic treatments and sequential treatments applied in real-life practice. | throughout of treatment, 36 months | 
| The Rate of Response Rate | Response rate | throughout of treatment, 36 months | 
| Progression free survival time | Progression free survival | throughout of treatment, 36 months | 
| Overall survival time | Overall survival | throughout of treatment, 36 months | 
| The frequency of comorbidities | Comorbidities rate | throughout of treatment, 36 months | 
| Advers events rate | Advers events | throughout of treatment, 36 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Immunotherapy, Progression free Survival, Survival